Its noteworthy that even though OncoImmune's Phase 2 trial supposedly showed statistical efficacy in reducing deaths, the study did not get halted at interim, and at conclusion the drug did not get some kind of approval. I don't know anything about the adverse effects statistics, but I would suspect that Big Pharma has targeted not only CytoDyn, but OncoImmune, as well.
News 
Market Data 
Discover 
AI
